U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H9N4O2S.Na
Molecular Weight 272.259
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SULFADIAZINE SODIUM

SMILES

[Na+].NC1=CC=C(C=C1)S(=O)(=O)[N-]C2=NC=CC=N2

InChI

InChIKey=JLDCNMJPBBKAHH-UHFFFAOYSA-N
InChI=1S/C10H9N4O2S.Na/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10;/h1-7H,11H2;/q-1;+1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C10H10N4O2S
Molecular Weight 250.277
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/dosage/sulfadiazine.html

Sulfadiazine is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus. Sulfadiazine is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. This enzyme is needed for the proper processing of para-aminobenzoic acid (PABA) which is essential for folic acid synthesis. The inhibited reaction is necessary in these organisms for the synthesis of folic acid. Used for the treatment of rheumatic fever and meningococcal meningitis.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Sulfadiazine

Approved Use

Sulfadiazine tablets USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris. Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum, when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilusinfluenzae, when used concomitantly with adequate doses of penicillin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin.

Launch Date

7.753536E11
Curative
Sulfadiazine

Approved Use

Sulfadiazine tablets USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris. Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum, when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilusinfluenzae, when used concomitantly with adequate doses of penicillin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin.

Launch Date

7.753536E11
Curative
Sulfadiazine

Approved Use

Sulfadiazine tablets USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris. Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum, when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilusinfluenzae, when used concomitantly with adequate doses of penicillin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin.

Launch Date

7.753536E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
84.9 μg/mL
2 g 2 times / day steady-state, oral
dose: 2 g
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SULFADIAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.247 μg × h/mL
2 g 2 times / day steady-state, oral
dose: 2 g
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SULFADIAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.9 h
2 g 2 times / day steady-state, oral
dose: 2 g
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SULFADIAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Disc. AE: Stenocardia, Distress gastrointestinal...
Other AEs: Thrombopenia, Creatinine serum increased...
AEs leading to
discontinuation/dose reduction:
Stenocardia (grade 3, 5%)
Distress gastrointestinal (grade 3, 5%)
Skin rash (grade 3, 5%)
Other AEs:
Thrombopenia (9%)
Creatinine serum increased (5%)
Elevated liver enzyme levels (5%)
Malaise (23%)
Diarrhea (5%)
Sources: Page: p.36, 38
1 g 4 times / day steady, oral
Recommended
Dose: 1 g, 4 times / day
Route: oral
Route: steady
Dose: 1 g, 4 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.4
unhealthy, 29.81
n = 16
Health Status: unhealthy
Condition: Cerebral toxoplasmosis
Age Group: 29.81
Sex: M+F
Population Size: 16
Sources: Page: p.4
Disc. AE: Stevens Johnson syndrome, Thrombocytopenia...
Other AEs: Skin rash, Neutropenia...
AEs leading to
discontinuation/dose reduction:
Stevens Johnson syndrome (grade 3, 1.16%)
Thrombocytopenia (grade 4, 25%)
Major bleed (grade 4, 25%)
Other AEs:
Skin rash (1.16%)
Neutropenia (18.75%)
Febrile neutropenia (1.16%)
Sources: Page: p.4
6 g 1 times / day steady, oral (max)
Recommended
Dose: 6 g, 1 times / day
Route: oral
Route: steady
Dose: 6 g, 1 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.476
unhealthy, 33.8
n = 29
Health Status: unhealthy
Condition: Central nervous system toxoplasmosis
Age Group: 33.8
Sex: M+F
Population Size: 29
Sources: Page: p.476
Disc. AE: Skin rash, Neutropenia...
AEs leading to
discontinuation/dose reduction:
Skin rash (grade 3, 17.24%)
Neutropenia (grade 3, 3.45%)
Acute renal failure (grade 3, 6.9%)
Sources: Page: p.476
AEs

AEs

AESignificanceDosePopulation
Malaise 23%
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Creatinine serum increased 5%
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Diarrhea 5%
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Elevated liver enzyme levels 5%
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Thrombopenia 9%
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Distress gastrointestinal grade 3, 5%
Disc. AE
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Skin rash grade 3, 5%
Disc. AE
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Stenocardia grade 3, 5%
Disc. AE
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Febrile neutropenia 1.16%
1 g 4 times / day steady, oral
Recommended
Dose: 1 g, 4 times / day
Route: oral
Route: steady
Dose: 1 g, 4 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.4
unhealthy, 29.81
n = 16
Health Status: unhealthy
Condition: Cerebral toxoplasmosis
Age Group: 29.81
Sex: M+F
Population Size: 16
Sources: Page: p.4
Skin rash 1.16%
1 g 4 times / day steady, oral
Recommended
Dose: 1 g, 4 times / day
Route: oral
Route: steady
Dose: 1 g, 4 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.4
unhealthy, 29.81
n = 16
Health Status: unhealthy
Condition: Cerebral toxoplasmosis
Age Group: 29.81
Sex: M+F
Population Size: 16
Sources: Page: p.4
Neutropenia 18.75%
1 g 4 times / day steady, oral
Recommended
Dose: 1 g, 4 times / day
Route: oral
Route: steady
Dose: 1 g, 4 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.4
unhealthy, 29.81
n = 16
Health Status: unhealthy
Condition: Cerebral toxoplasmosis
Age Group: 29.81
Sex: M+F
Population Size: 16
Sources: Page: p.4
Stevens Johnson syndrome grade 3, 1.16%
Disc. AE
1 g 4 times / day steady, oral
Recommended
Dose: 1 g, 4 times / day
Route: oral
Route: steady
Dose: 1 g, 4 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.4
unhealthy, 29.81
n = 16
Health Status: unhealthy
Condition: Cerebral toxoplasmosis
Age Group: 29.81
Sex: M+F
Population Size: 16
Sources: Page: p.4
Major bleed grade 4, 25%
Disc. AE
1 g 4 times / day steady, oral
Recommended
Dose: 1 g, 4 times / day
Route: oral
Route: steady
Dose: 1 g, 4 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.4
unhealthy, 29.81
n = 16
Health Status: unhealthy
Condition: Cerebral toxoplasmosis
Age Group: 29.81
Sex: M+F
Population Size: 16
Sources: Page: p.4
Thrombocytopenia grade 4, 25%
Disc. AE
1 g 4 times / day steady, oral
Recommended
Dose: 1 g, 4 times / day
Route: oral
Route: steady
Dose: 1 g, 4 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.4
unhealthy, 29.81
n = 16
Health Status: unhealthy
Condition: Cerebral toxoplasmosis
Age Group: 29.81
Sex: M+F
Population Size: 16
Sources: Page: p.4
Skin rash grade 3, 17.24%
Disc. AE
6 g 1 times / day steady, oral (max)
Recommended
Dose: 6 g, 1 times / day
Route: oral
Route: steady
Dose: 6 g, 1 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.476
unhealthy, 33.8
n = 29
Health Status: unhealthy
Condition: Central nervous system toxoplasmosis
Age Group: 33.8
Sex: M+F
Population Size: 29
Sources: Page: p.476
Neutropenia grade 3, 3.45%
Disc. AE
6 g 1 times / day steady, oral (max)
Recommended
Dose: 6 g, 1 times / day
Route: oral
Route: steady
Dose: 6 g, 1 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.476
unhealthy, 33.8
n = 29
Health Status: unhealthy
Condition: Central nervous system toxoplasmosis
Age Group: 33.8
Sex: M+F
Population Size: 29
Sources: Page: p.476
Acute renal failure grade 3, 6.9%
Disc. AE
6 g 1 times / day steady, oral (max)
Recommended
Dose: 6 g, 1 times / day
Route: oral
Route: steady
Dose: 6 g, 1 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.476
unhealthy, 33.8
n = 29
Health Status: unhealthy
Condition: Central nervous system toxoplasmosis
Age Group: 33.8
Sex: M+F
Population Size: 29
Sources: Page: p.476
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 6.65 uM]
Drug as victim
PubMed

PubMed

TitleDatePubMed
Recombinant bactericidal/permeability-increasing protein (rBPI21) in combination with sulfadiazine is active against Toxoplasma gondii.
1999 Apr
Obstructive nephropathy due to sulfa crystals in two HIV seropositive patients treated with sulfadiazine.
1999 Aug
Sulfadiazine-induced crystalluria and renal failure in a patient with AIDS.
1999 May-Jun
Interleukin 6 may be an important mediator of trimethoprim-induced systemic adverse reaction resembling aseptic meningitis.
2000 Jul 10
Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim (trimazin 30%) after oral administration in non-fasted young pigs.
2001 Aug
Enhanced anti-Shigella activity of erythromycin supplemented with sulfadiazine.
2001 Dec
Systematic review of antimicrobial agents used for chronic wounds.
2001 Jan
Treatment of dogs infected with Hepatozoon americanum: 53 cases (1989-1998).
2001 Jan 1
Antimicrobial susceptibility of starter culture bacteria used in Norwegian dairy products.
2001 Jul 20
Inhibition of aerobic growth and nitrification of bacteria in sewage sludge by antibacterial agents.
2001 May
Burns and injuries resulting from the use of gel candles.
2001 May-Jun
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.
2001 Nov
Management of pressure ulcers.
2001 Nov
Myth: silver sulfadiazine is the best treatment for minor burns.
2001 Sep
The beneficial toxicity paradox of antimicrobials in leg ulcer healing impaired by a polymicrobial flora: a proof-of-concept study.
2002
Prevalence of moderate penicillin resistant invasive Neisseria meningitidis infection in Scotland, 1994-9.
2002 Apr
[Increased serum and urinary levels of silver during treatment with topical silver sulfadiazine].
2002 Feb
[Congenital toxoplasmosis: prevention in the pregnant woman and management of the neonate].
2002 Feb
Atypical anterior optic neuropathy caused by toxoplasmosis.
2002 Jan
The effectiveness of processed grapefruit-seed extract as an antibacterial agent: I. An in vitro agar assay.
2002 Jun
[Topical agents used in the treatment of burns].
2002 Mar-Apr
[Glanders--a potential disease for biological warfare in humans and animals].
2002 May
Confocal laser microscopic observation of glycocalyx production by Staphylococcus aureus in vitro.
2002 May
Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039.
2002 May 1
Effect of sulfadiazine and pyrimethamine on selected physiologic and performance parameters in athletically conditioned thoroughbred horses during an incremental exercise stress test.
2002 Spring
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Can also be used topically http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=018810&DrugName=THERMAZENE&ActiveIngred=SILVER%20SULFADIAZINE&SponsorApplicant=THEPHARMANETWORK%20LLC&ProductMktStatus=1&goto=Search.DrugDetails
Usual Adult Dose for Toxoplasmosis Toxoplasmic encephalitis: Initial dose: Pyrimethamine 200 mg orally once Maintenance dose: <60 kg: Sulfadiazine 1 g orally every 6 hours plus pyrimethamine 50 mg orally once a day. >=60 kg: Sulfadiazine 1500 mg orally every 6 hours plus pyrimethamine 75 mg orally once a day. In addition, leucovorin 10 to 20 mg/day orally (may increase up to 50 mg/day).
Route of Administration: Oral
Sulfadiazine inhibited Pseudomonas aeruginosa with MIC 256 ug/mL
Substance Class Chemical
Created
by admin
on Thu Jul 06 22:43:16 UTC 2023
Edited
by admin
on Thu Jul 06 22:43:16 UTC 2023
Record UNII
84CS1P306F
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SULFADIAZINE SODIUM
GREEN BOOK   INN   MART.   ORANGE BOOK   USP   WHO-DD  
INN  
Official Name English
SODIUM SULFADIAZINE
Common Name English
SULFADIAZINE SODIUM [GREEN BOOK]
Common Name English
NSC-117870
Code English
sulfadiazine sodium [INN]
Common Name English
N(SUP 1)-2-PYRIMIDINYLSULFANILAMIDE MONOSODIUM SALT
Common Name English
SULFADIAZINE SODIUM [ORANGE BOOK]
Common Name English
SULFADIAZINE SODIUM [MART.]
Common Name English
SULFADIAZINE SODIUM [USP MONOGRAPH]
Common Name English
Sulfadiazine sodium [WHO-DD]
Common Name English
BENZENESULFONAMIDE, 4-AMINO-N-2-PYRIMIDINYL-, MONOSODIUM SALT
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29739
Created by admin on Thu Jul 06 22:43:16 UTC 2023 , Edited by admin on Thu Jul 06 22:43:16 UTC 2023
Code System Code Type Description
EVMPD
SUB10696MIG
Created by admin on Thu Jul 06 22:43:16 UTC 2023 , Edited by admin on Thu Jul 06 22:43:16 UTC 2023
PRIMARY
INN
422
Created by admin on Thu Jul 06 22:43:16 UTC 2023 , Edited by admin on Thu Jul 06 22:43:16 UTC 2023
PRIMARY
PUBCHEM
15899898
Created by admin on Thu Jul 06 22:43:16 UTC 2023 , Edited by admin on Thu Jul 06 22:43:16 UTC 2023
PRIMARY
FDA UNII
84CS1P306F
Created by admin on Thu Jul 06 22:43:16 UTC 2023 , Edited by admin on Thu Jul 06 22:43:16 UTC 2023
PRIMARY
ChEMBL
CHEMBL439
Created by admin on Thu Jul 06 22:43:16 UTC 2023 , Edited by admin on Thu Jul 06 22:43:16 UTC 2023
PRIMARY
CAS
547-32-0
Created by admin on Thu Jul 06 22:43:16 UTC 2023 , Edited by admin on Thu Jul 06 22:43:16 UTC 2023
PRIMARY
DAILYMED
84CS1P306F
Created by admin on Thu Jul 06 22:43:16 UTC 2023 , Edited by admin on Thu Jul 06 22:43:16 UTC 2023
PRIMARY
EPA CompTox
DTXSID20203152
Created by admin on Thu Jul 06 22:43:16 UTC 2023 , Edited by admin on Thu Jul 06 22:43:16 UTC 2023
PRIMARY
DRUG BANK
DBSALT001400
Created by admin on Thu Jul 06 22:43:16 UTC 2023 , Edited by admin on Thu Jul 06 22:43:16 UTC 2023
PRIMARY
ECHA (EC/EINECS)
208-919-0
Created by admin on Thu Jul 06 22:43:16 UTC 2023 , Edited by admin on Thu Jul 06 22:43:16 UTC 2023
PRIMARY
RXCUI
220087
Created by admin on Thu Jul 06 22:43:16 UTC 2023 , Edited by admin on Thu Jul 06 22:43:16 UTC 2023
PRIMARY RxNorm
NCI_THESAURUS
C66566
Created by admin on Thu Jul 06 22:43:16 UTC 2023 , Edited by admin on Thu Jul 06 22:43:16 UTC 2023
PRIMARY
NSC
117870
Created by admin on Thu Jul 06 22:43:16 UTC 2023 , Edited by admin on Thu Jul 06 22:43:16 UTC 2023
PRIMARY
SMS_ID
100000086878
Created by admin on Thu Jul 06 22:43:16 UTC 2023 , Edited by admin on Thu Jul 06 22:43:16 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY